A meta-regression analysis of treatment effect modifiers in trials with flexible-dose oral sildenafil for erectile dysfunction in broad-spectrum populations

International Journal of Impotence Research

Volumn 18, Issue 6, 2006, Pages 559-565

  Kriston, L ^a   Harms, A ^a   Berner, M M ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Meta analysis; Phosphodiesterase inhibitors; Randomized controlled trials; Sildenafil

Indexed keywords

SILDENAFIL;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; ERECTILE DYSFUNCTION; HUMAN; MEDLINE; PRIORITY JOURNAL; PUBLICATION; REVIEW;

ADMINISTRATION, ORAL; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMPOTENCE; MALE; PIPERAZINES; REGRESSION ANALYSIS;

EID: 33750493582     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/sj.ijir.3901479     Document Type: Review

References (47)

1. Rosen RC, Fisher WA, Eardley I, Niederberger C, Nadel A, Sand M. The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004; 20: 607-617.
2. Nicolosi A, Glasser DB, Moreira ED, Villa M, Erectile Dysfunction Epidemiology Cross National Study Group. Prevalence of erectile dysfunction and associated factors among men without concomitant diseases: a population study. Int J Impot Res 2003; 15: 253-257.
3. Kubin M, Wagner G, Fugl-Meyer AR. Epidemiology of erectile dysfunction. Int J Impot Res 2003; 15: 63-71.
4. Brock G. Oral agents: first-line therapy for erectile dysfunction. Eur Urol Suppl 2002; 1: 12-18.
5. Gresser U, Gleiter CH. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil - review of the literature. Eur J Med Res 2002; 7: 435-446.
6. Carson CC, Rajfer J, Eardley I, Carrier S, Denne JS, Walker DJ et al. The efficacy and safety of tadalafil: an update. BJU Int 2004; 93: 1276-1281.
7. Hellstrom WJ. Vardenafil: a new approach to the treatment of erectile dysfunction. Curr Urol Rep 2003; 4: 479-487.
8. Carson CC, Burnett AL, Levine LA, Nehra A. The efficacy of sildenafil citrate (viagra) in clinical populations: an update. Urology 2002; 60(Suppl 2B): 12-27.
9. Berner MM, Kriston L, Harms A. Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixeddose regimen randomized controlled trials administering the International Index of Erectile Function in broad spectrum populations. Int J Impot Res 2006 (in print).
10. Burls A, Gold L, Clark W. Systematic review of randomised controlled trials of sildenafil (Viagra) in the treatment of male erectile dysfunction. Br J Gen Pract 2001; 51: 1004-1012.
11. Fink HA, Mac Donald R, Rutks IR, Nelson DB, Wilt TJ. Sildenafil for male erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med 2002; 162: 1349-1360.
12. Markou S, Perimenis P, Gyftopoulos K, Athanasopoulos A, Barbalias G. Vardenafil (Levitra) for erectile dysfunction: a systematic review and meta-analysis of clinical trial reports. Int J Impot Res 2004; 16: 470-478.
13. Eardley I, Mirone V, Montorsi F, Ralph D, Kell P, Warner MR et al. An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy. BJU Int 2005; 96: 1323-1332.
14. Rosen RC, Riley A, Wagner G. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-830.
15. Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 1999; 54: 346-351.
16. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
17. Deeks JJ, Higgins JPT, Altman DG. Analysing and presenting results. In: Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]; Section 8. The Cochrane Library, Issue 3, John Wiley & Sons, Ltd: Chichester, UK 2005.
18. Sharp SJ, Thompson SG, Altman DG. The relation between treatment benefit and underlying risk in meta-analysis. BMJ 1996; 313: 735-738.
19. Sterne JAC, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ 2001; 323: 101-105.
20. Lipsey MW, Wilson DB. Practical Meta-Analysis, Applied Social Research Methods Series, Vol. 49. Sage Publications: London, 2000.
21. Thompson SG, Sharp SJ. Explaining heterogeneity in metaanalysis: a comparison of methods. Stat Med 1999; 18: 2693-2708.
22. Wilson DB. SPSS, Stata, and SAS macros for performing meta-analytic analyses. http://mason.gmu.edu/~dwilsonb/ma.html. last uptated: 15-1-2002. accessed: 10-11-2003.
23. Becher E, Tejada NA, Gomez R, Decia R, Southern Latin America Sildenafil Study Group. Sildenafil citrate (Viagra) in the treatment of men with erectile dysfunction in southern Latin America: a double-blind, randomized, placebo-controlled, parallel-group, multicenter, flexible-dose escalation study. Int J Impot Res 2002; 14(Suppl 2): 33-41.
24. Cappelleri JC, Siegel RL, Osterloh IH, Rosen RC. Relationship between patient self-assessment of erectile function and the erectile function domain of the international index of erectile function. Urology 2000; 56: 477-481.
25. Chen KK, Hsieh JT, Huang ST, Jiaan DB, Lin JS, Wang CJ et al. ASSESS-3: a randomised, double-blind, flexible-dose clinical trial of the efficacy and safety of oral sildenafil in the treatment of men with erectile dysfunction in Taiwan. Int J Impot Res 2001; 13: 221-229.
26. Choi HK, Ahn TY, Kim JJ, Kim SC, Paick JS, Suh JK et al. A double-blind, randomised- placebo, controlled, parallel group, multicentre, flexible-dose escalation study to assess the efficacy and safety of sildenafil administered as required to male outpatients with erectile dysfunction in Korea. Int J Impot Res 2003; 15: 80-86.
27. Dinsmore WW, Hodges M, Hargreaves C, Osterloh IH, Smith MD, Rosen RC. Sildenafil citrate (Viagra) in erectile dysfunction: near normalization in men with broad-spectrum erectile dysfunction compared with age-matched healthy control subjects. Urology 1999; 53: 800-805.
28. Glina S, Bertero E, Claro J, Damiao R, Faria G, Fregonesi A et al. Efficacy and safety of flexible-dose oral sildenafil citrate (Viagra) in the treatment of erectile dysfunction in Brazilian and Mexican men. Int J Impot Res 2002; 14(Suppl 2): S27-S32.
29. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. New Engl J Med 1998; 338: 1397-1404.
30. Gomez F, Davila H, Costa A, Acuna A, Wadskier LA, Plua P et al. Efficacy and safety of oral sildenafil citrate (Viagra) in the treatment of male erectile dysfunction in Colombia, Ecuador, and Venezuela: a double-blind, multicenter, placebo-controlled study. Int J Impot Res 2002; 14(Suppl 2): S42-S47.
31. Kongkanand A, Ratana-Olarn K, Ruangdilokrat S, Tantiwong A, for the Thai investigators in ASSESS-2 Study Group. The efficacy and safety of oral sildenafil in Thai men with erectile dysfunction: a randomized, double-blind, placebo controlled, flexible-dose study. J Med Assoc Thai 2003; 86: 195-205.
32. Levinson IP, Khalaf IM, Shaeer KZ, Smart DO. Efficacy and safety of sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men in Egypt and South Africa. Int J Impot Res 2003; 15(Suppl 1): S25-S29.
33. Meuleman E, Cuzin B, Opsomer RJ, Hartmann U, Bailey MJ, Maytom MC et al. A dose-escalation study to assess the efficacy and safety of sildenafil citrate in men with erectile dysfunction. BJU Int 2001; 87: 75-81.
34. Tan HM, Moh CL, Mendoza JB, Gana T, Albano GJ, de la CR et al. Asian sildenafil efficacy and safety study (ASSESS-1): a double-blind, placebo-controlled, flexible-dose study of oral sildenafil in Malaysian, Singaporean, and Filipino men with erectile dysfunction. Urology 2000; 56: 635-640.
35. Young JM, Bennett C, Gilhooly P, Wessells H, Ramos DE. Efficacy and safety of sildenafil citrate (Viagra) in black and Hispanic American men. Urology 2002; 60(Suppl 2B): 39-48.
36. Higgins JPT, Thompson SG. Controlling the risk of spurious findings from meta-regression. Stat Med 2004; 23: 1663-1682.
37. Berlin JA, Santanna J, Schmid CH, Szczech LA, Feldman HI, Anti-Lymphocyte Antibody Induction Therapy Study Group. Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head. Stat Med 2002; 21: 371-387.
38. Schmid CH, Stark PC, Berlin JA, Landais P, Lau J. Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors. J Clin Epidemiol 2004; 57: 683-697.
39. Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 2001; 54: 1046-1055.
40. Martinez-Jabaloyas JM, Gil-Salom M, Villamon-Fort R, Pastor-Hernandez F, Martinez-Garcia R, Garcia-Sisamon F. Prognostic factors for response to sildenafil in patients with erectile dysfunction. Eur Urol 2001; 40: 641-646.
41. Jarow JP, Burnett AL, Geringer AM. Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment. J Urol 1999; 162: 722-725.
42. Virag R. Indications and early results of sildenafil (Viagra) in erectile dysfunction. Urology 1999; 54: 1073-1077.
43. Park K, Ku JH, Kim SW, Paick JS. Risk factors in predicting a poor response to sildenafil citrate in elderly men with erectile dysfunction. BJU Int 2005; 95: 366-370.
44. McMahon CG, Samali R, Johnson H. Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction. J Urol 2000; 164: 1192-1196.
45. Shabsigh R. Efficacy of sildenafil citrate (Viagra) is not affected by aetiology of erectile dysfunction. Int J Clin Pract Suppl 1999; 102: 19-20.
46. Stern JM, Simes RJ. Publication bias: evidence of delayed publication in a cohort study of clinical research projects. BMJ 1997; 315: 640-645.
47. Ioannidis JP. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. JAMA 1998; 279: 281-286.